Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration Eisai Feb 28, 2023 14:28 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」の中国における生物ライセンス申請（BLA）が優先審査に指定 Eisai Feb 28, 2023 09:50 JST Read More
Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd Olympus Feb 24, 2023 14:00 HKT/SGT Read More
Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd Olympus Feb 24, 2023 14:00 HKT/SGT Read More
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency Eisai Jan 27, 2023 10:46 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理 Eisai Jan 27, 2023 08:30 JST Read More
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel Eisai Jan 19, 2023 09:35 HKT/SGT Read More
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company Eisai Jan 19, 2023 08:07 HKT/SGT Read More
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 Eisai Jan 18, 2023 12:28 HKT/SGT Read More
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan Eisai Jan 16, 2023 17:56 HKT/SGT Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請 Eisai Jan 16, 2023 09:00 JST Read More
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 PCG Digital Jan 16, 2023 06:00 HKT/SGT Read More
